169 related articles for article (PubMed ID: 38238401)
1. Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y; Nakagomi T; Nagakubo Y; Goto T; Omata M
Sci Rep; 2024 Jan; 14(1):1594. PubMed ID: 38238401
[TBL] [Abstract][Full Text] [Related]
2. Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.
Nagakubo Y; Hirotsu Y; Yoshino M; Amemiya K; Saito R; Kakizaki Y; Tsutsui T; Miyashita Y; Goto T; Omata M
Sci Rep; 2024 May; 14(1):12480. PubMed ID: 38816489
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
Saito A; Terai H; Kim TJ; Emoto K; Kawano R; Nakamura K; Hayashi H; Takaoka H; Ogata A; Kinoshita K; Ito F; Shigematsu L; Okada M; Fukushima T; Mitsuishi A; Shinozaki T; Ohgino K; Ikemura S; Yasuda H; Kawada I; Soejima K; Nishihara H; Fukunaga K
Cancer Med; 2024 Feb; 13(4):e7077. PubMed ID: 38457233
[TBL] [Abstract][Full Text] [Related]
4. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
[TBL] [Abstract][Full Text] [Related]
5. Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
Murakami S; Yokose T; Shinada K; Isaka T; Katakura K; Ushio R; Kondo T; Kato T; Ito H; Saito H
Thorac Cancer; 2022 Nov; 13(22):3217-3224. PubMed ID: 36203199
[TBL] [Abstract][Full Text] [Related]
6. Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.
Sakaguchi T; Iketani A; Esumi S; Esumi M; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Yasui H; Taguchi O; Hataji O
Sci Rep; 2023 Aug; 13(1):13759. PubMed ID: 37612335
[TBL] [Abstract][Full Text] [Related]
7. Possible False Results With cobas
Kanaoka K; Tamiya A; Inagaki Y; Taniguchi Y; Nakao K; Takeda M; Matsuda Y; Okishio K; Shimizu S
Anticancer Res; 2023 Jun; 43(6):2771-2776. PubMed ID: 37247929
[TBL] [Abstract][Full Text] [Related]
8. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
Jatkoe T; Wang S; Odegaard JI; Velasco Roth AM; Osgood D; Martinez G; Lucas P; Curtin JC; Karkera J
J Mol Diagn; 2022 Nov; 24(11):1181-1188. PubMed ID: 35963523
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer.
Sakaguchi T; Iketani A; Furuhashi K; Nakamura Y; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Taguchi O; Hataji O
Thorac Cancer; 2021 Feb; 12(4):462-467. PubMed ID: 33314600
[TBL] [Abstract][Full Text] [Related]
10. Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.
Zhang L; Coffin J; Formenti K; Chu Q; Izevbaye I
BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35091437
[TBL] [Abstract][Full Text] [Related]
11. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S; González Á; Cunquero Tomas AJ; Calabuig Fariñas S; Ferrero M; Mirda D; Sirera R; Jantus-Lewintre E; Camps C
Expert Rev Mol Diagn; 2020 Jun; 20(6):575-582. PubMed ID: 32011193
[TBL] [Abstract][Full Text] [Related]
12. Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2.
Uchibori K; Takano N; Manabe R; Tsugitomi R; Ogusu S; Tozuka T; Sakamoto H; Yoshida H; Amino Y; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2021 Mar; 12(6):906-913. PubMed ID: 33528892
[TBL] [Abstract][Full Text] [Related]
13. Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.
Amemiya K; Hirotsu Y; Nagakubo Y; Mochizuki H; Higuchi R; Tsutsui T; Kakizaki Y; Miyashita Y; Oyama T; Omata M
Cancer Cytopathol; 2021 Sep; 129(9):729-738. PubMed ID: 33872472
[TBL] [Abstract][Full Text] [Related]
14. EGFR T751_I759delinsN Mutation in Exon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated Patient with NSCLC.
Chang ZT; Chan TM; Wu CE
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362239
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice.
Ariyasu R; Uchibori K; Ninomiya H; Ogusu S; Tsugitomi R; Manabe R; Sakamaoto H; Tozuka T; Yoshida H; Amino Y; Kitazono S; Yanagitani N; Takeuchi K; Nishio M
Thorac Cancer; 2021 Feb; 12(4):504-511. PubMed ID: 33350072
[TBL] [Abstract][Full Text] [Related]
16. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
18. Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non-small cell lung cancer specimens.
Wu W; Huang Y; Guo J; Xie X; Li H; Cao Z; Wei H; Wu C
Cancer Cytopathol; 2020 Aug; 128(8):545-552. PubMed ID: 32286726
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non-small cell lung cancer.
Iwama E; Yamamoto H; Okubo F; Ijichi K; Ibusuki R; Shiaraishi Y; Yoneshima Y; Tanaka K; Oda Y; Okamoto I
Thorac Cancer; 2023 Aug; 14(23):2288-2296. PubMed ID: 37345344
[TBL] [Abstract][Full Text] [Related]
20. EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits.
Bencze E; Bogos K; Kohánka A; Báthory-Fülöp L; Sárosi V; Csernák E; Bittner N; Melegh Z; Tóth E
Pathol Oncol Res; 2022; 28():1610607. PubMed ID: 36277960
[No Abstract] [Full Text] [Related]
[Next] [New Search]